Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol 2004;27(5):234-44
Date
12/17/2004Pubmed ID
15602105DOI
10.1097/01.wnf.0000145508.84389.87Scopus ID
2-s2.0-7444247368 (requires institutional sign-in at Scopus site) 37 CitationsAbstract
This review systematically examines the effects of botulinum toxin type A (BTX-A) on patient-reported outcomes across disorders using evidence-based criteria. The evidence provided by these studies ranged from randomized, controlled trials to case series. The effects of BTX-A on quality of life or global treatment outcomes were assessed in 48 studies across 16 different conditions. All but 7 of these reported benefits of BTX-A over baseline or the comparator condition (placebo or other treatment). The effects of BTX-A on impairment, activities, or participation were assessed in 46 studies across 17 different conditions. All but 4 reported benefits of BTX-A over baseline or the comparison group. The effects of BTX-A on satisfaction or preference were assessed in 14 studies across 11 different conditions, all of which reported high rates of satisfaction with BTX-A or preference over the comparator. These studies provide evidence that BTX-A exerts meaningful benefits on the quality of life of patients treated with this biologic agent.
Author List
Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann MMESH terms used to index this publication - Major topics in bold
Anti-Dyskinesia AgentsBotulinum Toxins, Type A
Evidence-Based Medicine
Humans
Movement Disorders
Patient Satisfaction
Quality of Life
Research Design
Treatment Outcome
